Loading...

GENNEX Gennex Laboratories Ltd Product Launches Announcement

Gnnx

GNNX

Gennex Laboratories Ltd

(GENNEX)

2025 Announcement

Show Summary

Summary

Board Meeting Notice

Product Approval

Transfer Requests Window

Compliance Certificate

Financial Results Published

Secretarial Compliance

Director Appointment

Director Resignation

Board Meeting Announcement

Product Approval

Compliance Certificate

Financial Results Published

Use of Proceeds Update

Director Resignation

Management Change

Board Meeting Notice

Compliance Certificate

Financial Results Announcement

Committee Reconstitution

Management Change

No Deviation Report

Board Meeting Notice

Test License Granted

New Product Approval

Compliance Certificate

Director Resignation

Management Changes

Management Change

AGM Notice Published

Financial Results

No Deviation Report

CFO Resignation

Submission of Certificate

Submission of Compliance Re...

Newspaper Publication

Compliance Certificate

Submission of Certificate

Compliance Certificate

Publication of Financial Re...

Appointment of Dr.S.CH. DHA...

Meeting Announcement

Resignation of Director

Resignation of Director

Newspaper Publication

Certificate Obtained

Financial Results Publication

Disclosure under Regulation...

Meeting of Board of Directors

Certificate Submission

Equity purchase disclosed

Disclosure of Share Purchase

Financial Statements

Rights Offerings

Rights Offerings

Name Change Approval

Late Submission

Financial Statements

Financial Statements

Asset Acquisitions

Annual Secretarial Complian...

Financial Statements Adoption

External Links:

Data:

Gennex Laboratories Ltd's subsidiary, Deccan Remedies Limited, has received approval from the Drugs Control Administration in Andhra Pradesh to manufacture additional products valid until May 28, 2028, including Tapentadol and Voriconazole.

AI Assistant

Gennex Laboratories Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.